Sividon Diagnostics | GenomeWeb

Sividon Diagnostics

Agendia is launching a patient access program to position MammaPrint in clinics, while other test makers are taking a wait-and-see approach.

The acquisition provides Myriad with the EndoPredict test, which is currently offered in Europe and is expected to launch in the US next year.

The analysis showed that one out of 227 node-negative breast cancer patients with the lowest EPclin scores by Sividon's EndoPredict test experienced recurrence over 10 years.

At the San Antonio Breast Cancer Symposium, a Sividon collaborator is scheduled to present a new study including a comparison between EndoPredict and Oncotype DX.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.